GlassScriptPhysician profile
Daniel George Juarez
NPI 1104525401
$2,269.01
in general payments reported to CMS, 2019-2025
11 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $201 · 2024: $508 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545 · Travel and Lodging: $724.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,544.67 |
| Travel and Lodging | $724.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $1,362.70 | 2023-2025 | Iovera, Zilretta, Exparel |
| Abbvie INC. | $212.58 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $172.91 | 2023-2025 | Belbuca, Xtampza |
| Painteq LLC | $156.80 | 2025 | Painteq |
| Pfizer INC. | $113.17 | 2023-2025 | |
| Electronic Waveform Lab, INC. | $79.92 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.11 | 2025 | Relistor, Trulance |
| Kowa Pharmaceuticals America, INC. | $43.40 | 2023 | Seglentis |
| Vertex Pharmaceuticals Incorporated | $42.23 | 2025 | |
| Nalu Medical, INC. | $18.00 | 2024 | Nalu Neurostimulation System |
| Curonix LLC | $14.19 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Juarez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.